Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –
unleashing tools to accelerate breakthroughs in human health – and
Visiopharm® today announced a collaboration to pair the company’s
Hyperion™ and Hyperion+™ Imaging Systems with Visiopharm Phenoplex™
analysis software for simplified image processing and enhanced
spatial pathology insights, building on the success of a
co-marketing agreement announced last year.
Visiopharm, a leader in AI-driven digital pathology analysis
software, and Standard BioTools, a life science preferred provider
of innovative tools for exploratory and translational research,
have worked together to develop the first of several specific
algorithms and workflows that will provide out-of-the-box solutions
and accelerate delivery of results for high-plex imaging
studies.
The unique Standard BioTools™ single-step staining process and
simultaneous 40-plex imaging deliver biomarker-rich data in a
single scan for tissue microarrays and formalin-fixed,
paraffin-embedded tissue sections, providing enough datapoints to
thoroughly phenotype and decipher cellular composition and
function. Integrating Phenoplex into Hyperion and Hyperion+ Imaging
Systems will bring a powerful, unified image analysis pipeline to
Imaging Mass Cytometry™ (IMC™) users, who will be able to more
easily extract and more quickly act on meaningful biological data
from their IMC investigations.
This close partnership offers one of the most effective
solutions to date, in which Visiopharm software reads native MCD
files, the output image file from Standard BioTools imaging
systems, directly linking MCD™ Viewer to Phenoplex software.
Phenoplex then employs the Visiopharm file conversion tool to
create pyramidal TIFF images out of MCD files for large image
formats that contain more markers for deeper analysis.
The Phenoplex workflow includes an AI tissue segmentation step,
an AI-based nuclear segmentation step, cellular boundary detection
that can include use of the Standard BioTools IMC Cell Segmentation
Kit, cellular phenotyping, data exploration and image QC, spatial
analyses, and a wide range of data/image export formats.
The powerful combination of Standard BioTools proven high-plex
imaging with successful AI-driven software from Visiopharm will
provide a simple and efficient way for translational and clinical
researchers to generate and analyze high-plex spatial data from the
tumor microenvironment, making it easier to investigate therapeutic
and drug responses and arrive at confident decisions impacting
healthcare.
“We are delighted to embark on this partnership with Standard
BioTools to bring our Phenoplex image analysis to Hyperion Imaging
System users everywhere,” said Louise Armstrong, PhD, Chief
Commercial Officer at Visiopharm. “We have been working to improve
and simplify the image analysis of high-plex images like IMC
imagery and look forward to collaborating on evolving our analysis
solution to meet the needs of researchers in this space.”
“With this collaboration, Standard BioTools becomes one of the
first companies to bundle a system with a complete solution,” said
Michael Egholm, PhD, President and Chief Executive Officer of
Standard BioTools. “This seamless pipeline transition from
instrument to data analysis will be a big step for multiplex
imaging, leading the way for high-plex adoption so customers no
longer need to spend their time piecing together freeware to
develop a pipeline.”
Use of Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements regarding the potential
benefits of research conducted using Standard
BioTools products and technologies and anticipated benefits
to Standard BioTools of an expanded collaboration.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including but not limited to
risks relating to interruptions or delays in the supply of
components or materials for, or manufacturing of, Standard
BioTools products; potential product performance and quality
issues; intellectual property risks; competition; uncertainties in
contractual relationships; and reductions in research and
development spending or changes in budget priorities by customers.
Information on these and additional risks and uncertainties and
other information affecting Standard BioTools’ business and
operating results is contained in its Annual Report on Form 10-K
for the year ended December 31, 2021, and in its other filings
with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date
hereof. Standard BioTools disclaims any obligation to
update these forward-looking statements except as may be required
by law.
About Standard BioTools
Standard BioTools Inc. (Nasdaq:LAB), previously known
as Fluidigm Corporation, is driven by a bold purpose
– unleashing tools to accelerate breakthroughs in human
health. Standard BioTools has an established portfolio of
essential, standardized next-generation technologies that help
biomedical researchers develop medicines faster and better. As a
leading solutions provider, the company provides reliable and
repeatable insights in health and disease using its proprietary
mass cytometry and microfluidics technologies, which help transform
scientific discoveries into better patient outcomes. Standard
BioTools works with leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide, focusing on the most pressing
needs in translational and clinical research, including oncology,
immunology, and immunotherapy. Learn more
at www.standardbio.com or connect with us
on Twitter®, Facebook®, LinkedIn,
and YouTube™. Standard BioTools, the Standard
BioTools logo, Fluidigm, the Fluidigm logo,
“Unleashing tools to accelerate breakthroughs in human health,”
Hyperion, Hyperion+, Imaging Mass Cytometry, IMC, and MCD are
trademarks and/or registered trademarks of Standard BioTools
Inc. or its affiliates in the United States and/or other countries.
All other trademarks are the sole property of their respective
owners. Standard BioTools products are provided
for Research Use Only. Not for use in diagnostic
procedures.
About Visiopharm A/S
Visiopharm is a world leader in AI-driven precision pathology
software. Its pioneering image analysis tools support thousands of
scientists, pathologists, and image analysis experts in academic
institutions, the biopharmaceutical industry, and diagnostic
centers. AI-based image analysis and tissue mining tools support
research and drug development research worldwide, while CE-IVD APPs
provide decision support. With the most advanced and sophisticated
artificial intelligence and deep learning, Visiopharm delivers
tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2002 and is privately owned. The
company operates internationally with over 750 customer accounts
and countless users in more than 40 countries. The company
headquarters are in Denmark’s Medicon Valley, with offices in
Sweden, England, Germany, the Netherlands, and the United
States.
Available Information
Standard BioTools uses its website (standardbio.com),
investor site (investors.standardbio.com), corporate Twitter
account (@Standard_BioT), Facebook page
(facebook.com/StandardBioT), and LinkedIn page
(linkedin.com/company/standard-biotools) as channels of
distribution of information about its products, its planned
financial and other announcements, its attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and Standard
BioTools may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor Standard BioTools’ website and its social media accounts in
addition to following its press releases, SEC filings,
public conference calls, and webcasts.
Investors:Peter DeNardo415 389
6400ir@standardbio.com
Source: Standard BioTools Inc.
Standard BioTools (NASDAQ:LAB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Standard BioTools (NASDAQ:LAB)
Historical Stock Chart
From Sep 2023 to Sep 2024